Form 4: Labcorp CEO Exercises RSUs, Adjusts Holdings

Labcorp's President and CEO, Adam H. Schechter, reported the exercise and vesting of Restricted Stock Units and subsequent tax-related stock dispositions.

Summary

• Adam H. Schechter, President & CEO and Director of Labcorp Holdings Inc., reported multiple transactions involving company common stock and Restricted Stock Units (RSUs).
• On February 6, 2026, Schechter acquired 4,460 shares of common stock through the vesting of RSUs and disposed of 1,315 shares at $277.20 to satisfy tax withholding obligations, resulting in 90,719 directly owned common shares.
• On February 7, 2026, an additional 3,249 shares of common stock were acquired through RSU vesting, bringing direct common share ownership to 93,968.
• On February 9, 2026, 1,352 shares were disposed of at $274.01 to cover further tax withholding obligations, leaving 92,616 directly owned common shares.
• The RSU vestings on February 6, 2026, were part of a grant that vests in three equal annual installments beginning on February 6, 2025.
• The RSU vestings on February 7, 2026, were part of a grant that began vesting on February 7, 2024, and are now fully vested.
• Schechter holds an aggregate of 15,430 Restricted Stock Units following these reported transactions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While there are tax-related sales, the underlying RSU vestings represent a planned increase in the CEO's direct equity holdings, aligning his interests with shareholders.

Positives

• Adam H. Schechter, President & CEO, increased his direct common stock holdings by a net of 5,042 shares (4,460 + 3,249 1,315 1,352) through RSU vesting, indicating continued equity ownership and alignment with shareholder interests.
• The vesting of Restricted Stock Units represents a planned compensation event, reflecting the achievement of prior performance or service conditions.

Negatives

• Dispositions of common stock totaling 2,667 shares were made solely to satisfy tax withholding obligations, which is a common practice and not indicative of a negative outlook.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction, as it is solely a report of insider transactions.

Industry Context

StockSavvy.ai notes that insider transaction reports like this Form 4 are routine disclosures for executives of publicly traded companies. The vesting of RSUs and subsequent tax-related sales are standard practices for executive compensation and do not inherently signal a change in company fundamentals or industry trends. Labcorp operates in the highly competitive diagnostics and drug development services industry, where executive equity alignment is a common compensation strategy.

Corporate Governance

Stakeholder Impact

• Shareholders: The increase in the CEO's direct common stock holdings through RSU vesting generally aligns management's interests with those of shareholders, potentially fostering long-term value creation.

Key Dates

Recommendation

The Form 4 filing details routine insider transactions related to executive compensation (RSU vesting and tax-related sales). These transactions are expected and do not provide new fundamental information about Labcorp's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The net increase in the CEO's direct holdings is a positive for alignment but not a strong catalyst for a 'buy' or 'sell' decision.

Keywords

Labcorp Holdings Inc., LH, Adam H. Schechter, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Compensation, CEO Stock Transactions, Equity Holdings